MDGL
Madrigal Pharmaceuticals Inc
513.20$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | +324.8% | +66.2% | +32.8% | +55.0% | +35.0% | +11.8% | -3.0% | +17.0% | – | |
| – | +5.2% | +18.3% | +278.6% | +238.4% | +60.1% | +31.0% | +100.9% | +99.9% | +34.9% | +9.8% | +49.0% | – | |
| – | – | – | – | +328.7% | +66.4% | +32.9% | +53.5% | +32.1% | +10.2% | -4.1% | +14.0% | – | |
| – | -0.4% | +0.8% | -0.2% | -3.3% | -62.7% | +72.2% | +22.4% | +221.7% | -33.2% | -6.5% | -16.1% | – | |
| – | +68.7% | +73.6% | +30.5% | +2.0% | +173.1% | -42.9% | +5.5% | +18.1% | +0.0% | +28.4% | +7.8% | – | |
| – | +18.9% | +29.8% | +16.1% | -0.1% | -5.4% | +27.1% | +18.3% | +52.7% | -7.0% | +5.9% | +0.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +13.3% | -3.3% | -4.7% | +0.6% | -4.9% | -5.8% | -1.0% | +128.3% | +11.4% | -5.8% | +1.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +27.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.